SLC5A2 and Abnormal renal physiology: Initially, it was thought that this may be solely responsible for the bodyweight loss caused by SGLT2 inhibitors, but other mechanisms for bodyweight loss were also suggested, because weight reductions were also observed even when administered to renal dysfunction patients with impaired urine secretion [25].